Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...

INDIANAPOLIS — Eli Lilly filed lawsuits against compounding pharmacies and an Indianapolis weight loss company over the use of Zepbound and Mounjaro. On April 1, 2025, Lilly filed lawsuits against two ...

Eli Lilly is buying Verve Therapeutics, developer of gene-editing treatments for cardiovascular disease, for $1 billion plus ...

Eli Lilly is reducing the price of the highest doses of its popular drug Zepbound for folks who aren't using insurance.

Eli Lilly ( LLY 0.90%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following ...

The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in a head-to-head study of the two drugs.

Boston-based Verve is a rare example of a gene editing company targeting a disease that affects a large population, offering ...

U.S. drugmaker Eli Lilly said on Monday it will offer the higher dose versions of its popular weight-loss drug Zepbound on its website LillyDirect. The company said 12.5 milligrams and 15 mg doses of ...

Eli Lilly ( LLY 0.36%) has been a great growth pick for investors over the past few years. The pharma company, thanks to its ...

Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...

An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the ...

Eli Lilly said Tuesday that it will acquire Verve Therapeutics, a biotech developing gene-editing therapies for cardiovascular disease.